In spite of major advances in diagnosis and treatment of prostate cancer in the last few years, a signi®cant proportion of patients will progress to advanced metastatic disease, for which no effective therapy is available. The need for improved treatment for advanced disease has led to extensive gene discovery efforts aimed at identi®cation and characterization of new genes implicated in prostate cancer. These genes are expected to help not only in elucidating the molecular mechanisms underlying the initiation and progression of the disease, but also to lead to the development of new therapeutic approaches. Of special interest are novel cell surface antigens that can serve as good targets for antibody therapy due to the recently proven ef®cacy of monoclonal antibodies (MAbs) in cancer, including the approval of Rituxan IDEC/ Genentech 1 for advanced B-cell lymphoma and Herceptin Genentech 1 for metastatic breast cancer.
Desirable cell surface targets for prostate cancer therapeutics should be: (a) expressed at a signi®cant level in a large patient population, preferably in advanced and metastatic stages of the disease; and (b) have a restricted expression pattern in normal tissues to minimize potential adverse effects. Of advantage are antigens expressed in a hormone-independent manner, which could be accessible during hormone ablation therapy and in hormonerefractory patients.
What novel genes have been identi®ed as potential targets for antibody therapy and how feasible is this approach in treating prostate cancer?
A handful of novel cell surface antigens with potential antibody therapeutic utility in prostate cancer have been identi®ed to date. These include: prostate-speci®c membrane antigen (PSMA); prostate stem cell antigen (PSCA); and six transmembrane epithelial antigen of the prostate (STEAP). These antigens are characterized by signi®cant expression in different stages of the disease, including metastatic lesions, and a restricted expression in normal tissues, predominantly in the prostate Ð a non-essential organ. Such characteristics make these antigens attractive targets for prostate cancer antibody therapy. The emergence of new technologies for the generation of therapeutic humanized or fully human antibodies, together with the availability of improved toxins and radioisotopes, facilitate the generation of safe and ef®cacious therapeutic antibodies, either in a naked or a conjugated form. Antibodies to PSMA are currently being tested in phase I clinical trials, while antibodies to PSCA are in advanced pre-clinical development.
Can you tell us something of your work at UroGenesys in this area?
UroGenesys, Inc. is engaged in the discovery and validation of novel, clinically relevant antigens implicated in cancer and their utilization for development of new therapeutic and diagnostic products. Prostate cancer has been part of a major programme at UroGenesys since its inception. Using a series of proprietary patient derived xenograft mouse models that re¯ect different stages of the disease, the company has succeeded in the identi®cation of over 40 novel antigens. These are highly expressed in local and/or metastatic disease, with very restricted expression in vital organs. Over a dozen of these antigens are cell surface targets amenable to antibody therapy, including PSCA and STEAP.
PSCA is expressed in over 80% of patients with local prostate cancer and in 100% of bone metastatic lesions. Expression levels are correlated with increased tumour stage, grade and progression to androgen independence. Studies carried out at UroGenesys have demonstrated that MAbs speci®c to PSCA signi®cantly retard the growth of established orthotopic human tumours and inhibit metastatic spread to distal sites, leading to signi®cant prolongation of the survival of tumourbearing mice. Genentech, Inc, which has licensed the rights for PSCA antibody therapy from UroGenesys, is currently developing anti-PSCA MAbs towards clinical development.
STEAP is expressed at high levels in all patient populations representing different stages of prostate cancer, including advanced hormone-refractory disease, as well as bone and lymph node metastatic lesions. Although normal expression of STEAP is restricted almost exclusively to the prostate, it has been detected at high levels in other epithelial tumour cell lines, such as colon, bladder, pancreatic and ovarian cancers. STEAP structure and localization implies its potential function as a transporter protein. These features make STEAP an attractive target for antibody as well vaccine and small molecule therapeutics.
Antigen expression in multiple solid tumours and its amenability to different therapeutic approaches are features shared by many antigens within UroGenesys' product candidate portfolio, including PSCA. The ability to develop and test more than one therapeutic approach will allow UroGenesys not only to increase the probability of generating a successful therapy, but will also provide for potential combination therapies that may have more impact on the disease than single therapeutic approach alone.
New funding initiatives in prostate cancer
Prostate cancer is high on the list of UK cancer priorities and a new funding initiative is in progress. In 1999, the Cancer Research Funders Forum (CRFF) was set up to improve the co-ordination of cancer research and treatment in the UK. This group consists of the main funders of UK cancer research, including the Cancer Research Campaign, the Imperial Cancer Research Fund, the Medical Research Council (MRC) and the Department of Health. The ®rst meeting of the CRFF took place in January 2000 and the group immediately recognized the importance of prostate cancer.
The MRC established a committee on behalf of the CRFF to review UK activities in prostate cancer research, clinical trials, training and career development and to identify and address any obstacles to progress. The committee met three times in February, May and June 2000. The main ®ndings were that the UK spends disproportionately little on prostate cancer and that prostate cancer research in the UK is fragmented and disparate. An important recommendation was that a small number of centres of research excellence should be established, combining basic and clinical scientists and fostering translational research in prostate cancer. The committee was in¯uenced by the success of US Government funding for SPOREs (Specialized Programs of Research Excellence). There are four such centres for prostate cancer research in the US: Baylor College of Medicine (Houston, Texas), John Hopkins in Baltimore, the University of Michigan and the University of California in San Francisco.
The UK prostate cancer research community were asked to put forward proposals to the CRFF in October 2000. On the basis of the preliminary proposals, seven groups were asked to submit full proposals to compete for two prostate cancer research centre awards, bidding for funding of £0.5 million a year for 5 years. The seven centres asked to prepare bids were University College London, Newcastle, Shef®eld/York, Cardiff, Institute Cancer Research, Manchester and Imperial College.
The University College London (UCL) bid is coordinated by Professor John Masters, who has worked at The Institute of Urology at UCL for 25 years and is an expert in the molecular cell biology of prostate cancer. The Institute of Urology provides a match for the US Specialized Program of Research Excellence, as this is where many of the UKs leading clinicians in prostate cancer surgery, radiology, histopathology, radiotherapy and brachytherapy, chemotherapy and laser therapy work. The prostate cancer clinicians work side-by-side with a team of basic research scientists in The Prostate Cancer Research Centre undertaking world class translational research partly funded by the US National Institutes of Health. UCL is putting forward an exciting programme of innovative translational research in prostate cancer, and will continue to be a leading centre for improving the treatment of men with prostate cancer in the UK.
Gene/environment interaction studies in prostate cancer A group headed by Dr Ros Eeles at the Institute of Cancer, Sutton, UK are currently seeking extension of their research programme on gene/environment interactions in prostate cancer. The research funded by the Prostate Cancer Charitable Trust has been running since 1997 and a 3-year extension is being requested.
Previous studies have indicated a genetic predisposition to prostate cancer. The evidence for the involvement of environmental factors, such as occupation, diet, sexual factors, in prostate cancer is also considerable. Identi®ca-tion of risk factors for the development of the disease would enable targeting screening and the undertaking of preventative strategies.
The aims of the proposed programme are three-fold:
1 To identify genetic risk factors for prostate cancer. 2 To identify environmental (lifestyle) risk factors for prostate cancer. 3 To identify interactions between genetic and environmental risk factors.
Genetic risk factors are being studied through screening of prostate cancer patients, speci®cally by identifying genetic changes in DNA isolated from blood samples. Environmental factors are being identi®ed through the use of prostate cancer patient questionnaires. Finally, an analysis of the interaction between genetic make-up and the environment will be conducted. To date, DNA from 275 patients diagnosed with prostate cancer at less than 60 years of age has been analysed.
Two important ®ndings have been made:
Mutatations in the gene coding for a glutathione Stransferase P1 (GST P1), an enzyme involved in activation and detoxi®cation of carcinogens, is associated with a 1.8-fold increased risk of prostate cancer. Mutatations in the gene (SRD5A2) that controls male hormone metabolism is associated with a 2-fold increased risk of prostate cancer.
The GST supergene family includes several loci with wellcharacterized polymorphisms. Approximately 50% of the Caucasian population are homozygous for deletions in GSTM1 and about 20% are homozygous for GSTT1. This results in conjugation de®ciency of mutagenic electrophiles to glutathione. The GSTP1 gene has a polymorphism at codon 105, resulting in an Ile to Val substitution, which consequently lowers the enzymatic activity of the protein. This has also been suggested as a putative highrisk genotype in various other cancers.
DNA samples from 178 prostate cancer patients at a single UK clinic have also been analysed by the group. Results show that polymorphisms in the human androgen receptor (hAR) gene are correlated with a poor prognosis (Edwards S et al. Int J Cancer (Pred Oncol) 1999; 84: 458±465). Lymphocyte DNA was genotyped for (CAG)n and (GGC)n polymorphisms, both of which have previously been linked to increased prostate cancer risk. Results indicated that stage, grade and GGC repeat length were individually signi®cant factors associated with disease-free survival and overall survival. The relative risk of relapse for men with more than 16 GGC repeats was 1.74 (95% CI 1.08±2.79). As the (GGC)n effect was strongest in early stage tumours, it was suggested that the marker may help forecast aggressive behaviour and identify those patients requiring more radical treatment.
The team at the Institute of Cancer have also developed a faster and more sensitive method of analysing the structure of a candidate gene (BRCA2) in young prostate cancer cases (Edwards S et al. Human Mutation, 2001 (in press) ). This gene increases the risk of both prostate and breast cancer. All types of mutation, particularly point mutations, are more reliably and robustly detected than by other commonly used conformational sensitive methods, eg, conformational sensitive gel electrophoresis (CSGE). The approach developed at the Institute of Cancer relies on band shift detections and is able to detect single base substitutions that have previously only been detectable by direct sequencing methods.
PSA Prostate Cancer Screening Trial
The Medical Research Council (MRC) and the Cancer Research Campaign recently considered a funding application from Dr Sue Moss (Institute of Cancer Research, Royal Cancer Hospital, Surrey, UK) and Professor Freda Alexander (University of Edinburgh, UK) for a prostate screening trial. Both organizations independently assessed the proposal, with a view to co-funding the study. While, recognizing that evidence of the bene®ts and costs of screening was needed (particularly in terms of mortality, morbidity and the impact of screening and treatment on quality of life), the proposal raised a number of complex and dif®cult issues.
Study design
The objectives of the UK trial were as follows:
To determine whether there was a reduction in mortality from prostate cancer in men offered screening by PSA testing. To determine the increased physical morbidity from false positive screening tests and from treatment. To estimate resource costs and cost-effectiveness. To determine the psychological advantages and disadvantages of screening.
The study aimed to screen 36 000±46 000 men (depending on uptake) aged 55±69. A total of 150±280 000 would be randomized to control or study groups in a ratio of 2X1. Men in the study group would be offered screening by PSA testing at 2-y intervals, with counselling and informed consent prior to testing. All men with a total PSA 4 ng/ ml would be referred to a urologist for further assessment, including biopsy where indicated. Men in the control group would receive the usual medical care.
Prostate cancer mortality at 10 y of follow-up would be determined; this would exclude deaths from prostate cancer diagnosed before the trial. Mortality between the total study group and the control would be compared and the trial was designed to have an 80% power to detect a 15±20% reduction in mortality in the group offered screening. Other parameters that would have been measured include:
Uptake, referral, biopsy and cancer detection rates. Prognostic factors in different groups. Side-effects of biopsy and treatment.
Economic and psychological outcomes. Extent of screening in the control group.
The MRC have pointed out that the decision not to fund this does not rule out the possibility of funding a screening trial in the future when better diagnostic and prognostic markers for the detection of prostate cancer have been developed. However, by that time, it may be ethically and practically impossible to have an unscreened control group.
Percentage of carcinoma at radical prostatectomy is an independent predictor of recurrence A report has been made on the controversial issue of tumour size measurement as a predictor of disease recurrence after radical prostatectomy (Carvalhal GF et al. Cancer 2000; 89: 1308±1314) . A series of 595 patients with clinically localized prostate carcinoma were studied. The percentage of carcinoma in radical prostatectomy specimens from these patients was assessed microscopically through visual estimate. Of the 595 patients, 46 (8%) had evidence of tumour recurrence. The mean percentage of carcinoma in the prostatectomy specimen was 11.3% in the group of patients who did not have disease recurrence and 23.8% in the group of patients who did experience disease recurrence. The percentage of carcinoma, preoperative PSA levels, tumour differentiation (histologic Gleason grade) and pathologic stage all were signi®cant predictors of disease recurrence according to the KaplanMeier method. Only pathologic tumour stage, Gleason score, and percentage of carcinoma proved to be independent predictors of disease recurrence. The authors concluded that the visual estimate of the percentage of carcinoma in prostatic tissue specimens from patients who undergo radical prostatectomy is a practical, simple and inexpensive method that provides important prognostic information after radical prostatectomy.
3D conformal radiotherapy: pretreatment nomogram
Researchers at the Memorial Sloan-Kettering Cancer Center, NY, USA and the Cleveland Clinic, Ohio, USA have developed a nomogram to improve the accuracy of predicting outcome after three-dimensional radiotherapy for prostate cancer treatment (Kattan MW et al. J Clin Oncol 2000; 18: 3352±3359) .
A retrospective, non-randomized analysis was conducted of patients treated at the Memorial SloanKettering Cancer Center between 1988 and 1998. Clinical parameters of the 1042 patients that were studied included: stage, biopsy Gleason score, pre-treatment serum PSA level, administration of neoadjuvant androgen deprivation therapy, and the dose of radiation delivered. Biochemical (PSA) treatment failure was de®ned as three consecutive rises in serum PSA. The nomogram developed aimed to predict the probability of remaining free from biochemical recurrence for 5 years.
External validation was based on a cohort of patients treated at the Cleveland Clinic. The Somers' D method of analysis was employed. This uses a range of coef®cient values from 7 1 to 1 to test the predictive accuracy associated with a model. On this scale, 0 represents no association at all, while 1 (or 7 1) represents perfect positive (or negative) association. The validation showed that the nomogram had a Somers' D rank correlation between predicted and observed failure times of 0.52. When compared with seven of the best previously developed risk strati®cation systems, this new nomogram gave more accurate predictions (Somers' D coef®cient 0.47).
TUVP vs TURP: 3-year outcome
A recently published study shows that transurethral electrovaporisation of the prostate (TUVP) was comparable to transurethral resection of the prostate (TURP) at 3-year follow-up (Hammadeh MY et al. BJU Int 2000; 86: 64±651). A total of 104 men admitted for surgery for benign prostatic hyperplasia were randomised to treatment with either TUVP (mean age 67.5 y) or TURP (mean age 70.2 y). In each arm, 51, 47 and 40 patients completed 1, 2 or 3 y of follow-up, respectively. Patients were assessed at baseline and during the follow-up using the International Prostate Symptoms Score (IPSS), maximum urinary¯ow rate (Qmax) and postvoid residual (PVR) urine.
Results showed that both groups had comparable mean IPSS, Qmax and PVR at baseline. At 3 years, the mean (s.d.) improvement in IPSS in the TUVP group was 4.1 (3.3) and in the TURP group, 7.1 (6.2). The mean (s.d.) improvement in Qmax was 22.2 (8.5) and 18 (7.1) ml/sec in the TUVP and TURP groups, respectively. The mean (s.d.) decrease in PVR was 30 (38) ml and 21.9 (26.2) ml in the TUVP and TURP groups, respectively. Side-effects and complications, eg, erectile dysfunction and retrograde ejaculation, were comparable in both groups.
